SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck is trending as retail investors speculate on potential buyout targets, specifically Sellas Life Sciences and others, driven by the need to secure new oncology assets ahead of the upcoming Keytruda patent cliff. Community discussions are heavily focused on the mathematical case for multi-billion dollar acquisition premiums, with debates raging over whether developmental-stage biotechs can command historical blockbuster valuations.

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

ASML Holding NV - New York Shares

ASML Holding NV

ASML is trending as a cornerstone of the AI infrastructure boom, with the community closely monitoring its earnings and supply chain dominance as a critical bottleneck for advanced chip production. Investors are actively discussing the company's monopoly on EUV lithography, its strategic role in supporting major foundry buildouts like Terafab, and recent bullish analyst outlooks that emphasize its long-term compounding potential despite short-term volatility.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is gaining significant momentum following the announcement of a multi-year partnership extension with Apple to supply custom ASIC silicon through 2031. Community sentiment remains highly focused on the stock's long-term potential in AI infrastructure and data center networking, with many traders actively monitoring key resistance levels for a breakout.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as smartphones, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

Taiwan Semiconductor is trending due to reports that major AI chip designers are exploring Intel as a secondary manufacturing partner, as the foundry giant struggles to meet unprecedented demand for its capacity. The community is actively monitoring the supply chain bottlenecks, analyzing technical support levels, and debating whether the recent market activity is a healthy consolidation or a signal of broader sector volatility.

Listed Funds Trust - Roundhill Magnificent Seven ETF

Roundhill Magnificent Seven ETF

Investors are closely watching the Roundhill Magnificent Seven ETF (MAGS) as it demonstrates a critical structural rebound, with the community actively debating whether this movement represents a healthy rotation back into mega-cap tech leadership or simply a temporary safe haven amidst broader market uncertainty. Technical indicators showing a potential reversal pattern are fueling excitement among bulls who believe current valuations in these high-growth names are now too attractive to ignore.

UNI is the governance token for Uniswap, an Automated Market Marker DEX on the Ethereum blockchain. The UNI token allows token holders to participate in the governance of the protocol. Key decisions such as usage of the treasury or future upgrades can be decided through a governance vote.

UniSwap

Uniswap is seeing heightened activity driven by a critical governance proposal to activate the protocol's fee switch and execute a significant token burn, which the community views as a major step toward long-term deflationary value. Investors are currently focused on these technical updates and institutional interest, with many debating the token's upside potential in the current market cycle.

ProShares Trust II - ProShares Ultra Silver 2x Shares

ProShares Ultra Silver

ProShares Ultra Silver is attracting significant retail attention as traders speculate on a potential short squeeze amid reports of tight physical silver supplies and industrial demand. Community members are actively debating the asset's volatility and the impact of broader economic factors like USD strength and geopolitical tensions on silver's price action.

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of therapeutics for metabolic dysfunction-associated steatohepatitis. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals is drawing intense community focus as investors debate whether the company will be acquired by a major pharmaceutical player or continue its strategy of aggressive pipeline expansion and R&D spending. While shareholders are optimistic about Rezdiffra's market adoption and potential combination therapies, the stock faces volatility as the community remains divided over management's path to long-term profitability versus building a massive standalone metabolic disease franchise.

BlackRock, Inc. engages in the provision of investment, advisory, and risk management solutions. Its products include single-asset and multi-asset portfolios. The company was founded by Laurence Douglas Fink and Robert Steven Kapito in 1988 and is headquartered in New York, NY.

Blackrock Inc.

BlackRock is currently trending as investors scrutinize its growing exposure to the private credit market amidst withdrawal limitations and broader sector-wide liquidity concerns. Market participants are also closely watching BlackRock's aggressive push into tokenization through its iShares platform, which remains a key talking point as institutional interest in blockchain-based financial infrastructure intensifies.

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Celcuity Inc

Celcuity Inc. is experiencing significant investor attention as the community weighs the company's recent progress, including a major equity offering priced at $38 and ongoing anticipation for upcoming Phase 3 data and potential FDA regulatory milestones. Traders are actively debating whether this movement represents a sustainable long-term opportunity driven by strong institutional support from firms like Baker Bros, or a speculative cycle influenced by high short interest and binary event volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers

TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting...

TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update

TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update PR...

TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference PR...

TuHURA Biosciences (NASDAQ:HURA) Earns Outperform Rating from Analysts at Citizens Jmp

Citizens Jmp initiated coverage on shares of TuHURA Biosciences in a report on Monday. They issued an "outperform" rating and a $9.00 price objective for the company...

TuHURA Biosciences (NASDAQ:HURA) Rating Lowered to "Sell" at Wall Street Zen

Wall Street Zen lowered shares of TuHURA Biosciences from a "hold" rating to a "sell" rating in a report on Saturday...

TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028

TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028 TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028 PR Newswire TAMPA, Fla., April 22, 2026 Credit...

TuHURA Biosciences, Inc. (NASDAQ:HURA) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of TuHURA Biosciences, Inc. (NASDAQ:HURA - Get Free Report) have received an average recommendation of "Moderate Buy" from the four analysts that are presently covering the stock, Marketbeat...

TuHURA Biosciences (NASDAQ:HURA) Raised to Hold at Wall Street Zen

Wall Street Zen upgraded TuHURA Biosciences from a "sell" rating to a "hold" rating in a research report on Wednesday...

Brookline Capital Markets Comments on HURA Q1 Earnings

TuHURA Biosciences, Inc. (NASDAQ:HURA - Free Report) - Equities researchers at Brookline Capital Markets issued their Q1 2026 earnings per share estimates for TuHURA Biosciences in a research note issued on Thursday, April 9th. Brookline Capital Markets analyst K. Raja forecasts that the company wil...

FY2029 EPS Forecast for TuHURA Biosciences Lifted by Analyst

TuHURA Biosciences, Inc. (NASDAQ:HURA - Free Report) - Equities research analysts at Brookline Capital Markets upped their FY2029 earnings per share (EPS) estimates for shares of TuHURA Biosciences...

This account has been verified as an official HURA representative.

Verified Account

Tu HURA Responder

TuHURA Biosciences, Inc. is a clinical-stage immuno-oncology company, which engages in the development of novel technologies to overcome resistance to cancer immunotherapy. Its lead product candidate, IFx2.0, is an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. The company was founded by Michael Lawman, Patricia Lawman and James A. Bianco on May 4, 2023 and is headquartered in Tampa, FL.

TuHURA Biosciences Inc.

This Small-Cap Biotech Stock Has Sparked A 7,000% Surge In Retail Chatter — Here’s Why

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$2.39
Prev Close	$2.34
Open	$2.33
Dividend Yield	0.00%
50-Day Moving Average	$2.33
Beta	0.79
Avg. Volume	736,245.13
PE Ratio	-3.96

52-Week High	$3.90
52-Week Low	$0.41
Market Capitalization	$152.2M
EPS (Annual)	-$0.6272
Price to Book	6.63
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

HURATuHURA Biosciences Inc.

Latest HURA News